With the strike of COVID-19 global pharma events, including DIA, OCT and BIO, kept their events virtual in 2020 and 2021. However, now, with some restrictions lifted people start looking forward to having more face-to-face interaction, while getting tired of virtual events.
In this episode we host Josh Karanasios, the founder of Jam55, who will share his projections on what Pharma and CRO networking will look like in 2022.

00:00 Introduction
01:18 Current situation in the life sciences event industry
03:24 How effective are online life sciences events vs face-2-face in terms ROI?
05:50 Other online formats healthcare and life sciences experts can leverage from
09:07 Key disadvantages of online events
12:23 Will the pharmaceutical networking get back to normal?
14:11 Does the hybrid model in pharma and biotech networking stand a chance?

Enjoy and subscribe to our YouTube channel to be the first to know about new content on clinical research.

Webpage: [ Ссылка ].
Experience: [ Ссылка ].
Blog, articles, case studies: [ Ссылка ].
LinkedIn: [ Ссылка ]

✉Reach out to become the next speaker: pr@oct-clinicaltrials.com
✉Submit an RFP for clinical services: info@oct-clinicaltrials.com

Jam55 is a micro events platform for hosting online experiences that captivate and engage your audience. More details at [ Ссылка ]

#cro #octclinical #pharmaevents #networking

свернуть